MCID: LYM017
MIFTS: 70

Lyme Disease

Categories: Infectious diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lyme Disease

MalaCards integrated aliases for Lyme Disease:

Name: Lyme Disease 12 77 54 26 60 56 44 3 45 15 17 74
Lyme Borreliosis 12 54 26 60 15
Lyme Neuroborreliosis 12 56 45 74
Neuroborreliosis 12 74
Borreliosis 54 56
Infection Due to Borrelia Burgdorferi Sensu Lato 26
Infection by Borrelia Burgdorferi 26
Borrelia Burgdorferi Infection 26
Neurological Lyme Disease 12
B. Burgdorferi Infection 26
Bannworth's Syndrome 12
Borrelia Infections 74
Bannwarth Syndrome 12
Borreliosis, Lyme 26
Lym 77

Characteristics:

Orphanet epidemiological data:

60
lyme disease
Inheritance: Not applicable; Prevalence: >1/1000 (Europe),1-5/10000 (France); Age of onset: All ages;

Classifications:



Summaries for Lyme Disease

MedlinePlus : 44 Lyme disease is a bacterial infection you get from the bite of an infected tick. The first symptom is usually a red rash, which may look like a bull's eye. But not all people with Lyme disease have a rash. As the infection spreads to other parts of the body, you may have A fever A headache Body aches A stiff neck Fatigue Lyme disease can be hard to diagnose because many of its symptoms are like those of the flu and other diseases. And you may not have noticed a tick bite. Your health care provider will look at your symptoms and medical history to figure out whether you have Lyme disease. Lab tests may not always give a clear answer until you have been infected for at least a few weeks. Antibiotics can cure most cases of Lyme disease. The sooner treatment begins, the quicker and more complete the recovery. After treatment, some patients may still have muscle or joint aches and nervous system symptoms. This is called post-treatment Lyme disease syndrome (PTLDS). Long-term antibiotics have not been shown to help with PTLDS. However, there are ways to help with the symptoms of PTLDS, and most patients do get better with time. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Lyme Disease, also known as lyme borreliosis, is related to choroiditis and multifocal choroiditis, and has symptoms including fever, fatigue and headache. An important gene associated with Lyme Disease is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Doxycycline and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and skin, and related phenotypes are arthritis and cranial nerve paralysis

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, has material basis in Borrelia burgdorferi, which is transmitted by blacklegged tick (Ixodes scapularis) or transmitted by western blacklegged tick (Ixodes pacificus). The infection has symptom fever, has symptom headache, has symptom fatigue, and has symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.

Genetics Home Reference : 26 Lyme disease is an infectious disease caused by Borrelia burgdorferi bacteria. The bacteria are transferred to humans by tick bite, specifically by blacklegged ticks (commonly known as deer ticks). The condition is named for the location in which it was first described, the town of Lyme, Connecticut.

NIH Rare Diseases : 54 Lyme disease is the most common tickborne infectious disease in the United States. Early signs and symptoms of the condition include fever, chills, muscle pain, headache, and joint pain. As the condition progresses, affected people may experience heart problems, Bell's palsy, arthritis, abnormal muscle movement, speech problems and cognitive (thinking) abnormalities. Please visit the Center for Disease Control and Prevention's Web site for a more comprehensive list of symptoms. Lyme disease is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of infected blacklegged ticks. Certain features of the condition, including whether or not an affected person will develop medication-resistant chronic arthritis, is thought to be influenced by genetic factors (certain human leukocyte antigen genes). Treatment generally includes antibiotics to address the bacterial infection and other medications (i.e. pain medications) to relieve symptoms.

CDC : 3 Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks.  Laboratory testing is helpful if used correctly and performed with validated methods. Most cases of Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat. The ticks that transmit Lyme disease can occasionally transmit other tickborne diseases as well.

Wikipedia : 77 The Crawford expedition was a campaign on the western front of the American Revolutionary War, and one... more...

Related Diseases for Lyme Disease

Diseases related to Lyme Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 489)
# Related Disease Score Top Affiliating Genes
1 choroiditis 30.3 CFH TNF
2 multifocal choroiditis 30.1 CFH TNF
3 brucellosis 30.0 CD40LG IL6 TNF
4 pertussis 30.0 IL1B IL6 TNF
5 legionellosis 30.0 IL1B TLR2 TNF
6 peripheral nervous system disease 30.0 IL6 TLR9 TNF
7 multiple sclerosis 30.0 CLDN11 IL1B IL6 TNF
8 complex regional pain syndrome 29.9 IL1B IL6 TNF
9 neurosyphilis 29.9 TLR1 TLR2 TLR6
10 chronic fatigue syndrome 29.9 IL1B IL6 TNF
11 juvenile rheumatoid arthritis 29.8 IL1B IL6 TNF
12 pericarditis 29.8 IL1B IL6 TNF
13 prosthetic joint infection 29.8 IL1B TLR2
14 cytomegalovirus infection 29.8 IL1B IL6 TNF
15 myocarditis 29.8 CD40LG IL6 TNF
16 endocarditis 29.8 HSPD1 IL6 TLR2 TNF
17 synovitis 29.7 IL1B IL6 TNF
18 louse-borne relapsing fever 29.7 CFHR1 IL6 TNF
19 chlamydia 29.7 HSPD1 IL1B IL6 TLR2 TNF
20 meningitis 29.6 IL1B IL6 TLR2 TLR9 TNF
21 scrub typhus 29.6 IL1B TLR2 TNF
22 meningoencephalitis 29.6 CD40LG IL6 TLR9
23 psoriatic arthritis 29.6 IL1B IL6 TNF
24 keratitis, hereditary 29.6 IL1B TLR2 TLR9
25 adult-onset still's disease 29.5 IL1B IL6 TNF
26 exanthem 29.4 IL6 TLR9 TNF
27 connective tissue disease 29.4 CD40LG HSPD1 IL6 TLR9 TNF
28 bacterial meningitis 29.4 IL1B IL6 TLR2 TLR9 TNF
29 membranoproliferative glomerulonephritis 29.4 C3 C4A CFH
30 rheumatoid arthritis 29.4 CD40LG IL1B IL6 TLR2 TNF
31 q fever 29.4 IL1B IL6 TLR1 TLR2 TNF
32 leptospirosis 29.4 IL1B IL6 TLR1 TLR2 TNF
33 otitis media 29.4 IL1B IL6 TLR2 TNF
34 chagas disease 29.3 IL1B IL6 TLR2 TNF
35 rheumatic disease 29.3 CD40LG IL1B TLR9 TNF
36 lupus erythematosus 29.3 C3 C4A CD40LG TNF
37 adult respiratory distress syndrome 29.1 C4A IL6 TNF
38 common variable immunodeficiency 29.0 CD40LG IL6 TLR2 TLR9 TNF
39 glomerulonephritis 28.9 C3 C4A CD40LG CFH IL1B TLR9
40 toxoplasmosis 28.6 CD40LG IL1B IL6 TLR2 TLR9 TNF
41 malaria 28.6 CD40LG IL1B IL6 TLR2 TLR9 TNF
42 bacterial infectious disease 28.5 HSPD1 IL1B IL6 TLR1 TLR2 TLR9
43 systemic lupus erythematosus 27.4 C3 C4A CD40LG IL1B IL6 TLR2
44 lyme disease - neurological complications 12.6
45 babesiosis 11.4
46 human granulocytic anaplasmosis 11.4
47 tick infestation 11.3
48 pars planitis 11.0
49 intermediate uveitis 11.0
50 atrophoderma of pierini and pasini 11.0

Graphical network of the top 20 diseases related to Lyme Disease:



Diseases related to Lyme Disease

Symptoms & Phenotypes for Lyme Disease

Human phenotypes related to Lyme Disease:

60 33 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 60 33 frequent (33%) Frequent (79-30%) HP:0001369
2 cranial nerve paralysis 60 33 frequent (33%) Frequent (79-30%) HP:0006824
3 joint swelling 60 33 frequent (33%) Frequent (79-30%) HP:0001386
4 meningitis 60 33 frequent (33%) Frequent (79-30%) HP:0001287
5 muscle weakness 60 33 occasional (7.5%) Occasional (29-5%) HP:0001324
6 nausea and vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002017
7 encephalitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002383
8 photophobia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000613
9 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
10 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
11 arthralgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002829
12 atrioventricular block 60 33 occasional (7.5%) Occasional (29-5%) HP:0001678
13 arrhythmia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011675
14 memory impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0002354
15 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
16 paresthesia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003401
17 amaurosis fugax 60 33 occasional (7.5%) Occasional (29-5%) HP:0100576
18 headache 60 33 occasional (7.5%) Occasional (29-5%) HP:0002315
19 insomnia 60 33 occasional (7.5%) Occasional (29-5%) HP:0100785
20 uveitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000554
21 skin nodule 60 33 occasional (7.5%) Occasional (29-5%) HP:0200036
22 dermal atrophy 60 33 occasional (7.5%) Occasional (29-5%) HP:0004334
23 behavioral abnormality 60 Occasional (29-5%)
24 peripheral neuropathy 60 Occasional (29-5%)

Symptoms:

12
  • fever
  • fatigue
  • headache
  • skin rash called erythema migrans

UMLS symptoms related to Lyme Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Lyme Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 C3 C4A CFHR1 CLDN11 HSPD1 TLR1

MGI Mouse Phenotypes related to Lyme Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 C3 CD40LG CFH IL1B IL6 TLR1
2 immune system MP:0005387 10.06 C3 CD40LG CFH IL1B IL6 TLR1
3 mortality/aging MP:0010768 10 C3 CD40LG CFH HSPD1 IL1B IL6
4 nervous system MP:0003631 9.85 C3 CD40LG CFH CLDN11 HSPD1 IL1B
5 renal/urinary system MP:0005367 9.5 C3 CD40LG CFH IL6 TLR2 TLR7
6 reproductive system MP:0005389 9.23 C3 CD40LG CLDN11 HSPD1 IL6 TLR6

Drugs & Therapeutics for Lyme Disease

Drugs for Lyme Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
2
Ceftriaxone Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73384-59-5 5479530 5361919
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5479529 5361202
6
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
7
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
8
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
9
Azithromycin Approved Phase 4,Phase 1,Phase 2 83905-01-5 447043 55185
10
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
15
Cortisone Experimental Phase 4 53-06-5 222786
16 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antimalarials Phase 4,Phase 3,Phase 2,Not Applicable
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
23 Cytochrome P-450 CYP3A Inhibitors Phase 4,Not Applicable
24 Antitubercular Agents Phase 4,Phase 2,Not Applicable
25 Antirheumatic Agents Phase 4
26 cefuroxime axetil Phase 4,Not Applicable
27 penicillins Phase 4
28 Erythromycin Ethylsuccinate Phase 4
29 Erythromycin Estolate Phase 4
30 Erythromycin stearate Phase 4
31 Gastrointestinal Agents Phase 4,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
33 Peripheral Nervous System Agents Phase 4
34 Hormone Antagonists Phase 4
35 Prednisolone acetate Phase 4
36 Antiemetics Phase 4,Not Applicable
37 Methylprednisolone Acetate Phase 4
38 glucocorticoids Phase 4
39 Autonomic Agents Phase 4
40 Hormones Phase 4
41 Antineoplastic Agents, Hormonal Phase 4
42 Protective Agents Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Neuroprotective Agents Phase 4
45
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
46
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
47 PENTA Phase 3
48
Aluminum sulfate Approved Phase 2,Phase 1 10043-01-3
49
Ethanol Approved Phase 1, Phase 2 64-17-5 702
50
Disulfiram Approved Phase 1, Phase 2 97-77-8 3117

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Persistent Lyme Empiric Antibiotic Study Europe Completed NCT01207739 Phase 4 Doxycycline;Clarithromycin and hydroxychloroquine;Placebo
2 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
3 Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
4 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
5 Study of Lyme Neuroborreliosis Completed NCT01635530 Phase 4 Doxycycline;Ceftriaxone
6 Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy Recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
7 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 Study and Treatment of Post Lyme Disease (STOP-LD) Completed NCT00000937 Phase 3 Antibiotics
9 Lyme Disease Prevention Program Completed NCT00000432 Phase 3
10 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease Completed NCT00001101 Phase 3 ceftriaxone;doxycycline
11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease Completed NCT00000938 Phase 3 ceftriaxone;doxycycline
12 Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever Completed NCT00237016 Phase 2, Phase 3 doxycycline treatment
13 Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis Completed NCT00138801 Phase 3 Ceftriaxone;Doxycycline
14 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis Enrolling by invitation NCT02553473 Phase 3 Doxycycline;Placebo
15 Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes Terminated NCT00958139 Phase 3
16 A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis Unknown status NCT00591318 Phase 1, Phase 2 ceftriaxone;Normal Saline
17 Brain Imaging and Retreatment Study of Persistent Lyme Disease Completed NCT00037479 Phase 2 ceftriaxone
18 Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation Completed NCT01243008 Phase 1, Phase 2 Application of SHB001
19 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Completed NCT01617083 Phase 2 Azithromycin;Placebo
20 Phase 1/2 Lyme Vaccine Study Completed NCT01504347 Phase 1, Phase 2
21 Xenodiagnosis After Antibiotic Treatment for Lyme Disease Recruiting NCT02446626 Phase 1, Phase 2 Xenodiagnosis
22 Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. Recruiting NCT03769194 Phase 2
23 Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease Not yet recruiting NCT03891667 Phase 1, Phase 2 Disulfiram 500 MG
24 A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
25 Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis Completed NCT03010228 Phase 1
26 Meditation and Stretching for Post Treatment Lyme Disease Syndrome Unknown status NCT02344537 Not Applicable
27 A School-Based Intervention to Reduce Lyme Disease Unknown status NCT00594997 Not Applicable
28 Cohort Description of Younger With AV-block Unknown status NCT03024047
29 Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis Unknown status NCT00942006 Not Applicable doxycycline;ceftriaxone
30 Antibiotic Treatment of Multiple Erythema Migrans Unknown status NCT01163994 Not Applicable ceftriaxone;doxycycline
31 Human Anaplasmosis in Eastern France Unknown status NCT01013636
32 Searching for Persistence of Infection in Lyme Disease Completed NCT01143558 Early Phase 1
33 Culture Media for Borrelia Burgdorferi Sensu Lato Completed NCT02145754 Not Applicable
34 Tick-borne Encephalitis and Possible Borrelial Serology Completed NCT03958058 Anti-borrelial antibiotic therapy
35 Analysis of Lyme Disease Lesions Completed NCT00132327
36 Erythema Migrans in Elderly Completed NCT03371563 Antibiotics
37 Sofia 2 Lyme FIA Whole Blood Clinical Study Completed NCT03238274
38 Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans Completed NCT03584919 Not Applicable doxycycline;Cefuroxime Axetil 500Mg Tab
39 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
40 Microbiologic Findings of Acute Facial Palsy in Children Completed NCT01537952
41 The Phenomenon of "Chronic Lyme"; an Observational Study Completed NCT01151150
42 Doxycycline in Therapy of Erythema Migrans Completed NCT01475708 Doxycycline
43 Study of Anti-HIV Therapy Intensification Completed NCT00034086 Not Applicable Lopinavir/Ritonavir;Lamivudine/Zidovudine;Tenofovir disoproxil fumarate;Lamivudine;Stavudine;Zidovudine;Didanosine
44 Duration of Antibiotic Treatment of Erythema Migrans Completed NCT00910715 Not Applicable doxycycline;doxycycline;placebo
45 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830 Not Applicable
46 Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel Recruiting NCT03581279 Not Applicable
47 Next Generation Sequencing Detection of Lyme Disease Recruiting NCT03505879
48 Evaluation, Treatment, and Follow-up of Patients With Lyme Disease Recruiting NCT00028080
49 A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations Recruiting NCT00001539
50 Borrelia Species in Cutaneous Lyme Borreliosis Recruiting NCT00576082

Search NIH Clinical Center for Lyme Disease

Cochrane evidence based reviews: lyme disease

Genetic Tests for Lyme Disease

Anatomical Context for Lyme Disease

MalaCards organs/tissues related to Lyme Disease:

42
Testes, Heart, Skin, Eye, T Cells, B Cells, Lung

Publications for Lyme Disease

Articles related to Lyme Disease:

(show top 50) (show all 4135)
# Title Authors Year
1
Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses. ( 30922701 )
2019
2
A Small Intergenic Region of lp17 is Required for Evasion of Adaptive Immunity and Induction of Pathology by the Lyme Disease Spirochete. ( 30945408 )
2019
3
Can Protected Areas Mitigate Lyme Disease Risk in Fennoscandia? ( 30963329 )
2019
4
Diversity of the Lyme Disease Spirochetes and its Influence on Immune Responses to Infection and Vaccination. ( 30967254 )
2019
5
Differences between palpation and static/dynamic tests to diagnose painful temporomandibular disorders in patients with Lyme disease. ( 30982182 )
2019
6
Laboratory Blood-Based Testing for Lyme Disease at a National Reference Laboratory. ( 30985892 )
2019
7
Antigen Engineering Approaches for Lyme Disease Vaccines. ( 30987418 )
2019
8
Erythema Migrans-Like Rash Mimicking Lyme Disease. ( 30996189 )
2019
9
Modeling transmission dynamics of lyme disease: Multiple vectors, seasonality, and vector mobility. ( 30997436 )
2019
10
Lyme disease research gets a needed boost. ( 31000643 )
2019
11
Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. ( 31014314 )
2019
12
Systematic review of Lyme disease in Turkey. ( 31018773 )
2019
13
Modeling Lyme disease host animal habitat suitability, West Point, New York. ( 31026171 )
2019
14
Lyme Disease. ( 31027665 )
2019
15
Neurocognition in Post-Treatment Lyme Disease and Major Depressive Disorder. ( 30418507 )
2019
16
Advanced Heart Block in Children with Lyme Disease. ( 30377753 )
2019
17
Evaluation of in vivo expressed Borrelia burgdorferi antigens for improved IgM serodiagnosis of early Lyme disease. ( 30344068 )
2019
18
Direct Diagnostic Tests for Lyme Disease. ( 30307486 )
2019
19
Limitations and Confusing Aspects of Diagnostic Testing for Neurologic Lyme Disease in the United States. ( 30257905 )
2019
20
Impacts of misclassification on Lyme disease surveillance. ( 30242983 )
2019
21
Multidisciplinary management of patients presenting with Lyme disease suspicion. ( 30190164 )
2019
22
Metabolites of prostaglandin synthases as potential biomarkers of Lyme disease severity and symptom resolution. ( 30121835 )
2019
23
Symptom Resolution in Pediatric Patients With Lyme Disease. ( 30060012 )
2019
24
Should Patients Infected with Borrelia burgdorferi No Longer Be Referred to as Having Lyme Disease? ( 30012359 )
2019
25
Cognitive Decline in Post-treatment Lyme Disease Syndrome. ( 29945190 )
2019
26
Insights From the Geographic Spread of the Lyme Disease Epidemic. ( 29920580 )
2019
27
Of ignorance and blindness: The Lyme disease paradigm. ( 29805049 )
2019
28
Incidence, presentation and management of Lyme disease in Dutch general practice. ( 29796639 )
2019
29
A ticking time bomb: A case of Lyme disease. ( 29748954 )
2019
30
Enhancement of Risk for Lyme Disease by Landscape Connectivity, New York, New York, USA. ( 31107213 )
2019
31
Lyme disease. ( 31104048 )
2019
32
Predicting spatiotemporal patterns of Lyme disease incidence from passively collected surveillance data for Borrelia burgdorferi sensu lato-infected Ixodes scapularis ticks. ( 31101553 )
2019
33
Future Lyme disease risk in the south-eastern United States based on projected land cover. ( 31099526 )
2019
34
Quantifying the relationship between human Lyme disease and Borrelia burgdorferi exposure in domestic dogs. ( 31099521 )
2019
35
Metamorphoses of Lyme disease spirochetes: phenomenon of Borrelia persisters. ( 31097026 )
2019
36
First case report of inducible heart block in Lyme disease and an update of Lyme carditis. ( 31096922 )
2019
37
Delineating surface epitopes of Lyme disease pathogen targeted by highly protective antibodies of New Zealand White rabbits. ( 31085705 )
2019
38
Heterodox and Orthodox Discourses in the Case of Lyme Disease: A Synthesis of Arguments. ( 31079542 )
2019
39
Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease. ( 31076888 )
2019
40
How general are generalist parasites? The small mammal part of the Lyme disease transmission cycle in two ecosystems in northern Europe. ( 31062166 )
2019
41
Factors Leading Municipal Authorities to Implement Preventive Interventions for Lyme Disease. ( 31052452 )
2019
42
Risk Factors of Lyme Disease: An Intersection of Environmental Ecology and Systems Science. ( 31052225 )
2019
43
A Multiple Streams Approach to Understanding the Issues and Challenges of Lyme Disease Management in Canada's Maritime Provinces. ( 31052190 )
2019
44
Linear B Cell Epitopes Derived from the Multifunctional Surface Lipoprotein BBK32 as Targets for the Serodiagnosis of Lyme Disease. ( 31043513 )
2019
45
Molecular testing of serial blood specimens from patients with early Lyme disease during treatment reveals changing co-infection with mixtures of Borrelia burgdorferi genotypes. ( 31036693 )
2019
46
Investigation of the performance of serological assays used for Lyme disease testing in Australia. ( 31034492 )
2019
47
Is it possible to Make a Correct Diagnosis of Lyme Disease on Symptoms Alone? Review of Key Issues and Public Health Implications. ( 31028718 )
2019
48
Structural determination of the complement inhibitory domain of Borrelia burgdorferi BBK32 provides insight into classical pathway complement evasion by Lyme disease spirochetes. ( 30897158 )
2019
49
The effects of multiyear and seasonal weather factors on incidence of Lyme disease and its vector in New York State. ( 30893749 )
2019
50
Co-infections in Persons with Early Lyme Disease, New York, USA. ( 30882316 )
2019

Variations for Lyme Disease

Expression for Lyme Disease

Search GEO for disease gene expression data for Lyme Disease.

Pathways for Lyme Disease

Pathways related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 C3 C4A CD40LG CFH IL1B IL6
2
Show member pathways
13.38 CD40LG IL1B IL6 TLR1 TLR2 TLR6
3
Show member pathways
13.19 IL1B TLR1 TLR2 TLR6 TLR7 TLR9
4
Show member pathways
13.13 C3 IL1B IL6 TLR1 TLR2 TLR6
5
Show member pathways
12.88 C3 C4A CD40LG HSPD1 IL1B IL6
6
Show member pathways
12.68 CD40LG IL1B IL6 TLR1 TLR2 TLR6
7
Show member pathways
12.64 CD40LG IL1B TLR1 TLR2 TLR6 TLR7
8 12.57 CD40LG IL1B TLR1 TLR2 TLR6 TLR7
9
Show member pathways
12.55 IL1B IL6 TLR2 TNF
10
Show member pathways
12.53 CD40LG IL1B IL6 TNF
11
Show member pathways
12.41 TLR1 TLR2 TLR6 TLR7 TLR9
12
Show member pathways
12.32 IL1B IL6 TLR2 TNF
13
Show member pathways
12.32 IL6 TLR1 TLR2 TLR6 TLR7 TLR9
14
Show member pathways
12.28 C3 CD40LG IL1B TLR2 TNF
15
Show member pathways
12.22 IL1B IL6 TLR2 TNF
16
Show member pathways
12.22 CLDN11 IL1B TLR1 TLR2 TLR6 TLR7
17
Show member pathways
12.2 IL1B IL6 TLR9 TNF
18 12.2 C4A HSPD1 IL1B IL6 TNF
19 12.19 IL6 TLR1 TLR2 TLR6 TLR7 TLR9
20
Show member pathways
12.09 IL1B TLR1 TLR2 TLR6 TLR7 TLR9
21
Show member pathways
11.98 IL1B IL6 TLR1 TLR2 TLR6 TLR7
22 11.97 IL1B IL6 TNF
23
Show member pathways
11.97 HSPD1 IL1B IL6 TLR1 TLR2 TLR6
24 11.94 IL1B IL6 TNF
25 11.92 IL1B IL6 TNF
26
Show member pathways
11.91 C3 C4A CFH
27 11.91 IL1B IL6 TLR2 TNF
28 11.88 IL1B IL6 TNF
29 11.88 IL1B IL6 TLR2 TNF
30 11.88 C3 TLR1 TLR2 TLR6 TLR7 TLR9
31 11.87 CD40LG IL1B TNF
32 11.86 IL1B IL6 TNF
33 11.84 C3 C4A IL1B IL6 TNF
34 11.81 IL1B IL6 TLR7 TLR9 TNF
35 11.72 IL1B IL6 TNF
36
Show member pathways
11.71 CD40LG IL1B IL6 TNF
37 11.69 C3 C4A CFH
38
Show member pathways
11.67 IL1B IL6 TLR1 TLR2 TLR6 TLR7
39 11.66 IL1B IL6 TNF
41 11.59 C3 HSPD1 IL1B IL6 TLR2 TNF
42 11.54 IL1B IL6 TNF
43 11.53 IL1B TLR2 TNF
44 11.53 C3 HSPD1 IL1B IL6 TLR1 TLR2
45 11.49 IL1B IL6 TNF
46 11.44 IL1B IL6 TLR9 TNF
47 11.42 CD40LG IL1B IL6 TLR2 TLR9 TNF
48 11.37 IL1B IL6 TNF
49 11.33 IL1B IL6 TNF
50 11.31 IL1B IL6 TNF

GO Terms for Lyme Disease

Cellular components related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.8 IL1B TLR1 TLR2 TLR6 TLR7 TLR9
2 extracellular space GO:0005615 9.61 C3 C4A CD40LG CFH CFHR1 HSPD1
3 phagocytic vesicle membrane GO:0030670 9.58 TLR1 TLR2 TLR6
4 blood microparticle GO:0072562 9.56 C3 C4A CFH CFHR1
5 endolysosome membrane GO:0036020 9.48 TLR7 TLR9
6 early phagosome GO:0032009 9.43 TLR7 TLR9
7 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR1 TLR2
8 membrane raft GO:0045121 8.92 TLR1 TLR2 TLR6 TNF
9 plasma membrane GO:0005886 10.2 C3 C4A CD40LG CLDN11 HSPD1 TLR1
10 extracellular region GO:0005576 10.02 C3 C4A CD40LG CFH CFHR1 IL1B

Biological processes related to Lyme Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 C3 CD40LG IL1B IL6 TLR1 TLR2
2 regulation of complement activation GO:0030449 9.94 C3 C4A CFH CFHR1
3 complement activation GO:0006956 9.93 C3 C4A CFH CFHR1
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 IL1B IL6 TNF
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 CD40LG IL1B IL6 TLR2 TLR6 TLR9
6 defense response to Gram-positive bacterium GO:0050830 9.9 IL6 TLR2 TNF
7 positive regulation of JNK cascade GO:0046330 9.9 IL1B TLR9 TNF
8 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TLR7 TLR9 TNF
9 positive regulation of T cell proliferation GO:0042102 9.89 CD40LG IL1B IL6
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 IL1B TLR2 TLR7 TLR9 TNF
11 positive regulation of interferon-gamma production GO:0032729 9.87 HSPD1 IL1B TNF
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 IL1B TLR6 TNF
13 positive regulation of phagocytosis GO:0050766 9.85 C3 IL1B TNF
14 positive regulation of interleukin-12 production GO:0032735 9.85 CD40LG HSPD1 TLR2 TLR9
15 positive regulation of interleukin-10 production GO:0032733 9.84 CD40LG HSPD1 TLR2 TLR9
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 IL1B TLR2 TNF
17 positive regulation of inflammatory response GO:0050729 9.83 TLR2 TLR7 TLR9 TNF
18 toll-like receptor signaling pathway GO:0002224 9.83 TLR1 TLR2 TLR6 TLR7 TLR9
19 negative regulation of neurogenesis GO:0050768 9.81 IL1B IL6 TNF
20 microglial cell activation GO:0001774 9.81 TLR2 TLR6 TLR7 TNF
21 positive regulation of glial cell proliferation GO:0060252 9.8 IL1B IL6 TNF
22 positive regulation of interleukin-8 production GO:0032757 9.8 IL1B TLR2 TLR7 TLR9 TNF
23 cell activation GO:0001775 9.78 TLR1 TLR2 TLR6
24 I-kappaB phosphorylation GO:0007252 9.77 TLR2 TLR7 TLR9
25 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.76 TLR7 TLR9 TNF
26 regulation of cytokine secretion GO:0050707 9.76 TLR1 TLR2 TLR6 TLR9
27 negative regulation of lipid catabolic process GO:0050995 9.75 IL1B TNF
28 positive regulation of JUN kinase activity GO:0043507 9.75 TLR6 TLR9 TNF
29 positive regulation of macrophage activation GO:0043032 9.74 HSPD1 TLR6
30 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.74 IL1B TNF
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IL1B TNF
32 toll-like receptor 9 signaling pathway GO:0034162 9.74 TLR7 TLR9
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL1B TNF
34 positive regulation of interleukin-8 secretion GO:2000484 9.74 TLR1 TLR2
35 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.74 IL1B TLR1 TLR6
36 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.73 TLR2 TLR9
37 complement activation, alternative pathway GO:0006957 9.73 C3 CFH
38 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.73 TLR7 TLR9
39 response to molecule of bacterial origin GO:0002237 9.73 TLR2 TLR9
40 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B TLR9
41 positive regulation of neuroinflammatory response GO:0150078 9.73 IL1B IL6 TNF
42 negative regulation of lipid storage GO:0010888 9.72 IL6 TNF
43 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
44 positive regulation of interferon-beta biosynthetic process GO:0045359 9.72 TLR7 TLR9
45 regulation of establishment of endothelial barrier GO:1903140 9.72 IL1B TNF
46 positive regulation of chemokine production GO:0032722 9.72 IL6 TLR2 TLR7 TLR9 TNF
47 positive regulation of apoptotic cell clearance GO:2000427 9.71 C3 C4A
48 positive regulation of fever generation GO:0031622 9.71 IL1B TNF
49 positive regulation of interleukin-18 production GO:0032741 9.71 TLR2 TLR9
50 regulation of immunoglobulin secretion GO:0051023 9.7 CD40LG TNF

Molecular functions related to Lyme Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.67 CFHR1 TLR1 TLR2 TLR6
2 transmembrane signaling receptor activity GO:0004888 9.62 TLR1 TLR6 TLR7 TLR9
3 cytokine activity GO:0005125 9.56 CD40LG IL1B IL6 TNF
4 interleukin-1 receptor binding GO:0005149 9.43 IL1B TLR9
5 siRNA binding GO:0035197 9.4 TLR7 TLR9
6 Toll-like receptor 2 binding GO:0035663 9.16 TLR1 TLR6
7 signaling pattern recognition receptor activity GO:0008329 9.13 TLR2 TLR7 TLR9
8 lipopeptide binding GO:0071723 8.8 TLR1 TLR2 TLR6

Sources for Lyme Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....